- Aytu BioPharma ( NASDAQ: AYTU ) announced on Wednesday the addition of a fourth patent for AR101/Enzastaurin to treat Vascular Ehlers-Danlos Syndrome, rare genetic disorder treatment.
- The patent has an expiry date of September 2041.
- The company expects to advance the PREVEnt Trial in VEDS for AR101 and dose the first patient by early 2023.
- "Adding this fourth patent to the portfolio deepens and broadens the intellectual property surrounding AR101/Enzastaurin for the treatment of inherited vascular disorders, including VEDS, for which we are advancing AR101 as an initial indication," the company said.
- Vascular Ehlers-Danlos syndrome (vEDS) is the most severe type of a hereditary disorder of the connective tissue.
- ( AYTU ) had risen 3.3% before the bell.
For further details see:
Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder